Trait Name |
Trait Full Name |
Panel |
Author |
Year |
Cases* |
Controls |
TAG Set Threshold |
CSEA p (chi2) |
Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 5.00e-2 | 2.95e-2 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 5.00e-2 | 4.96e-2 |
BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-4 | 2.57e-2 |
Breast Cancer | Breast Cancer | MTC | Hunter | 2007 | NA | 1145 | 5.00e-2 | 5.92e-4 |
CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-3 | 2.08e-2 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-2 | 4.98e-2 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 5.00e-2 | 1.33e-3 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 5.00e-2 | 1.75e-2 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-2 | 4.01e-2 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 3.09e-3 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 8.19e-4 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 5.30e-3 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 4.51e-2 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 2.54e-3 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 2.21e-3 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 1.28e-3 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 2.52e-3 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 5.83e-4 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 3.10e-4 |
Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 5.00e-2 | 4.09e-2 |
Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 1.00e-3 | 2.48e-2 |
Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 1.00e-4 | 2.28e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 3.60e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 1.00e-2 | 5.39e-3 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 1.58e-2 |
Anxiety | Anxiety Dichotomous | MTC | Otowa | 2016 | 7016 | 14745 | 5.00e-2 | 1.75e-2 |
Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 1.00e-3 | 3.86e-2 |
Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.24e-2 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.45e-3 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.19e-2 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 7.04e-3 |
Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.19e-3 |
BMI Physical Activity Interaction | BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.78e-2 |
BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 9.16e-3 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 4.50e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density All | MTC | Estrada | 2012 | NA | 32961 | 1.00e-4 | 4.78e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 32961 | 1.00e-3 | 4.35e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 5.00e-2 | 3.96e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 1.00e-2 | 3.26e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-3 | 1.16e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-3 | 3.86e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 2.50e-2 |
Facial Shape | Mod14 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.65e-2 |
Facial Shape | Mod3 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 7.00e-3 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.63e-3 |
Facial Shape | Mod49 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.05e-2 |
Facial Shape | Mod55 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 3.86e-2 |
Facial Shape | Mod9 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.45e-3 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 4.09e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 10555 | 5.00e-2 | 3.45e-2 |
Glycemic Traits | Fasting Insulin | ETC | Dupuis | 2010 | NA | 38238 | 5.00e-2 | 3.93e-2 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 2.12e-2 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 7.55e-4 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 3.37e-2 |
Lipoprotein Concentrations | Triglycerides | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 2.87e-2 |
Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 2.00e-2 |
Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 2.98e-2 |
Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.89e-2 |
Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 2.50e-4 |
Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 7.06e-5 |
Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 1.05e-4 |
Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 8.44e-3 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 1.69e-3 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.36e-4 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 9.31e-4 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 2.49e-4 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 5.84e-5 |
Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 2.27e-2 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 2.21e-2 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 8.07e-3 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 4.37e-3 |
Smoking | Log Age Onset Smoking | MTC | Furberg | 2010 | NA | 22438 | 5.00e-2 | 2.48e-2 |
Smoking | Log Age Onset Smoking | MTC | Furberg | 2010 | NA | 22438 | 1.00e-2 | 3.57e-2 |
Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 4.38e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 3.74e-2 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 2.44e-2 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 9.79e-3 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 1.98e-2 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 9.61e-3 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 9.68e-4 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 4.47e-2 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 3.41e-2 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 4.35e-2 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 2.29e-2 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 1.21e-3 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 7.97e-5 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 2.09e-2 |
Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-4 | 1.90e-2 |
Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-5 | 1.77e-2 |
Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 5.00e-2 | 3.97e-2 |
Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-4 | 4.35e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-5 | 2.70e-2 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 2.54e-2 |
Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 5.00e-2 | 7.75e-4 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 6.50e-3 |
Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 5.00e-2 | 1.77e-2 |
Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 1.00e-2 | 5.18e-3 |
Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 5.00e-2 | 2.86e-2 |
Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 3.62e-3 |
Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-3 | 2.86e-2 |
Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-2 | 6.76e-3 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 1.16e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 8.52e-3 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-4 | 2.59e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-5 | 7.37e-3 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 1.77e-2 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 3.00e-3 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 2.21e-3 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 6.48e-4 |
Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-3 | 4.61e-3 |
Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-4 | 1.39e-2 |
Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-5 | 1.34e-2 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 5.00e-2 | 4.48e-2 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 1.03e-3 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-3 | 9.57e-5 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-4 | 1.37e-2 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-5 | 3.86e-2 |
Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-4 | 3.43e-2 |
Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-5 | 1.58e-2 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-3 | 6.13e-3 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-4 | 9.05e-3 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 8.09e-4 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 5.00e-2 | 3.83e-2 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 1.98e-2 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 5.57e-5 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 4.89e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 5.54e-3 |
Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 1.00e-3 | 2.08e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 3.44e-3 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 5.00e-2 | 3.47e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 2.76e-2 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 3.30e-2 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-3 | 1.31e-3 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-4 | 9.41e-3 |
Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-2 | 4.52e-2 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-3 | 7.10e-3 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-4 | 9.67e-4 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-5 | 1.54e-4 |
Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-3 | 3.42e-2 |
Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-3 | 4.78e-2 |
Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-4 | 2.71e-2 |
PD | Parkinson's disease in GBA mutation carriers | ETC | Blauwendraat C | 2020 | 1,588 | 7,584 | 5.00e-2 | 4.69e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-4 | 3.13e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 2.83e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 8.16e-3 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-3 | 4.12e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-4 | 4.41e-2 |
Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-3 | 2.17e-2 |
Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-4 | 4.05e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.